Latest news with #Grifols
CBC
4 days ago
- Health
- CBC
Equipment failure at Winnipeg clinic caused blood plasma donor's kidney injury, lawsuit alleges
A Winnipeg man who donated blood plasma at a plasma clinic has filed a lawsuit claiming he suffered a serious kidney injury after something went wrong with the machine used in the procedure to withdraw blood. The plaintiff alleges the issue happened at the Grifols plasma collection facility, operated by the Ontario-based Canadian Plasma Resources, on Taylor Avenue in Winnipeg. It gives members of the public an honorarium payment for donating blood plasma, according to his lawsuit, filed July 9 with Manitoba Court of King's Bench. On July 15, 2023, the now 43-year-old donor went to the clinic for what the lawsuit describes as a routine plasma donation through a procedure called plasmapheresis, which involves blood passing through medical equipment to separate the plasma from the red blood cells. The red blood cells are then returned to the donor, along with replacement fluids. The procedure took about 90 minutes, and the donor left the Grifols facility around 10:45 a.m., the lawsuit says. Around noon, he began to feel ill and experienced symptoms such as blood in his urine and flu-like symptoms, it says. He called Canadian Plasma Resources to ask if the symptoms were anything he should be concerned about, but was told they were unaware of any issue that would cause them, his lawsuit says. He was advised to drink fluids and seek medical attention if the symptoms worsened. By shortly after 1 p.m., the donor began having significant abdominal pain, which continued to intensify, his lawsuit says. He was taken by ambulance to St. Boniface Hospital, where medical tests were done, including blood work, an ultrasound, a CT scan and urinalysis, to determine the source of his symptoms, the court document says. At the hospital, the donor got an email from Canadian Plasma Resources informing him that a "machine error" caused some red blood cells removed during the procedure to be "broken" and erroneously returned into his body along with the plasma, the claim says. It says he was advised the error may cause him to experience symptoms such as "blood in the urine, lower flank pain, shortness of breath, fever, weakness, confusion, or yellowing of the skin." Acute kidney injury: lawsuit The medical testing determined the donor had suffered an acute kidney injury as a result of the error, the claim alleges. He is suing Canadian Plasma Resources, which operates as Grifols, as well as three Grifols employees identified as health-care professionals. The allegations have not been tested in court, and the defendants have not filed statements of defence. The lawsuit says the man continued to experience fatigue and low energy that made him unable to return to work for about a month, after which he went back to work gradually. He continued suffering fatigue and low energy for about six months, the claim says. It also alleges he has suffered "non-reversible and permanent injuries" from the acute kidney injury, which may result in chronic kidney disease in his lifetime. The lawsuit seeks damages for pain, suffering, loss of enjoyment of life and lost income, among other damages. It alleges the employees at Grifols working at the time of the machine error failed to ensure the medical equipment was working safely and properly, and failed to recognize the equipment was malfunctioning. The employees also failed to advise the donor in a timely way that there was an error during his procedure and that he might experience complications, the claim alleges. CBC reached out to the plaintiff and his lawyer, as well as the defendants Grifols and Canadian Plasma Resources, but did not receive comment on the lawsuit before deadline. Grifols' website says plasma, the straw-coloured liquid portion of blood in which blood cells are suspended, is "used to manufacture life-saving and life-changing therapies." It says tens of thousands of Canadians benefit from plasma therapies used to treat a range of medical issues, such as immune deficiencies, respiratory disorders, and surgical bleeding, among others.
Bloomberg
24-06-2025
- Business
- Bloomberg
Grifols's Family Blood Is Thicker Than Water
Newsletter The Brink Spanish drugmaker under short seller attack paid a company linked to its founding family more than it paid other plasma suppliers By and Jorge Zuloaga Save Welcome to The Brink. It's Clara Hernanz Lizarraga and Jorge Zuloaga in Madrid, where we sifted through the documents on the Grifols investigation. We also have news on Lebanon and Wolfspeed. Follow this link to subscribe. Send us feedback and tips at debtnews@ The line between the Grifols family and the namesake Spanish drugmaker company founded in 1909 in Barcelona has always been a thin one. For much of its history, successive generations of the founding family held significant ownership stakes and occupied key executive roles — driving scientific innovation, overseeing operations, and guiding the company's global expansion.
Yahoo
24-06-2025
- Business
- Yahoo
Shift Toward Targeted Drug Delivery Systems and Non-invasive Treatment Options is Poised to Transform the Landscape
The global acute on chronic liver failure (ACLF) market is witnessing a transformation with a focus on innovative solutions like gene therapies and regenerative medicine. These advancements offer new ways to tackle the condition's root causes, while targeted drug delivery systems and non-invasive treatments promise more effective, patient-friendly options. However, the lack of FDA-approved therapies limits market growth. North America is expected to lead due to its robust healthcare infrastructure. Key market drivers include rising investments in R&D and the increasing prevalence of liver diseases. Companies like Grifols Therapeutics, GENFIT, and Martin Pharmaceuticals are pioneering progress in this burgeoning field. Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "Acute On Chronic Liver Failure Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to growing focus on innovative solutions like gene therapies and regenerative medicine technologies offers significant potential for the global acute on chronic liver failure market, introducing new ways to address the root causes of the condition. Additionally, the shift toward targeted drug delivery systems and non-invasive treatment options is poised to transform the treatment landscape, providing more effective and patient-friendly alternatives that could further propel market the lack of FDA-approved therapies for acute on chronic liver failure remains a key challenge, limiting the availability of effective treatment options and hindering market expansion. On a positive note, the continuous improvement of healthcare infrastructure in emerging economies presents a considerable opportunity for market growth, as increased access to treatments becomes more America is expected to dominate the global acute on chronic liver failure market due to established healthcare systems, high treatment adoption rates, and significant investments in healthcare infrastructure. Key Market Players and Competition SynopsisThe companies profiled in this report are based on extensive research and insights from primary experts, evaluating company coverage, product portfolios, and market penetration. The leading players in the global acute on chronic liver failure market include pharmaceutical companies making significant advancements in therapies for liver failure. These companies play a crucial role in improving patient outcomes and addressing the growing demand for effective treatments for liver diseases. How Can This Report Add Value to an Organization?Product/Innovation Strategy: This report provides comprehensive insights into the current treatments and market trends for acute on chronic liver failure, helping organizations identify opportunities for new product development. By focusing on unmet needs, particularly in the areas of antiviral therapies, liver support agents, and organ transplantation, companies can innovate to meet the growing demand for effective ACLF Strategy: To maintain a competitive edge in the acute on chronic liver failure market, companies should focus on improving the safety and efficacy of existing treatments, advancing liver transplantation technologies, and exploring strategic partnerships with research institutions and healthcare providers. Expanding market access in emerging markets and investing in public awareness campaigns will also be critical to gaining market - Drivers and Limitations The demand drivers for the global acute on chronic liver failure market are: Ongoing investment in research and development of new drug classes, including antivirals and immunosuppressants for acute on chronic liver failure, is propelling market growth The rising prevalence of chronic liver diseases, especially cirrhosis and chronic hepatitis, is contributing to a higher occurrence of acute on chronic liver failure, thereby fuelling the demand for effective treatments Limitations: The lack of FDA-approved therapies for acute on chronic liver failure restricts access to effective treatments, impeding market growth Some of the prominent pharmaceutical companies established in the global acute on chronic liver failure market include: Grifols Therapeutics LLC GENFIT Corp Martin Pharmaceuticals Key Topics Covered: 1. Global Acute On Chronic Liver Failure Market: Industry Outlook1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis of Acute On Chronic Liver Failure1.2.1 By Region1.3 Market Trends1.4 Clinical Trial Analysis1.4.1 By Phase1.5 Regulatory Landscape Analysis1.5.1 Legal Requirement and Framework in U.S.1.5.2 Legal Requirement and Framework in E.U.1.5.3 Legal Requirement and Framework in Asia-Pacific1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Restraints1.6.4 Market Opportunities2. Global Acute On Chronic Liver Failure Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Acute On Chronic Liver Failure Market (by Country)2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Acute On Chronic Liver Failure Market (by Country)2.2.3.1.1 Germany2.2.3.1.2 France2.2.3.1.3 Italy2.2.3.1.4 U.K.2.3 Asia-Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia-Pacific Acute On Chronic Liver Failure Market (by Country)2.3.3.1.1 Japan2.4 Rest-of-the-World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global Acute On Chronic Liver Failure Market: Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments by Company3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Grifols Therapeutics LLC3.2.1.1 Company Overview3.2.1.2 Product Portfolio3.2.1.3 Target Customers/End Users3.2.1.4 Key Personnels3.2.1.5 Analyst View3.2.2 GENFIT Corp3.2.2.1 Company Overview3.2.2.2 Product Portfolio3.2.2.3 Target Customers / End Users3.2.2.4 Key Personnels3.2.2.5 Analyst View3.2.3 Martin Pharmaceuticals3.2.3.1 Company Overview3.2.3.2 Product Portfolio3.2.3.3 Target Customers / End Users3.2.3.4 Key Personnels3.2.3.5 Analyst View4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Mint
23-06-2025
- Business
- Mint
Grifols Case Shows It Paid Family-Linked Entity More for Plasma
(Bloomberg) -- Spanish drugmaker Grifols SA paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator's findings submitted in a court case. Grifols paid Scranton Enterprises BV — one of its main shareholders — between 2% and 39% more annually for plasma than it paid other suppliers over five years, according to a document from the securities regulator filed with a Spanish court. Grifols also agreed to pay a fixed 16.5% mark up on costs to Scranton, according to the documents, which were seen by Bloomberg. Although Grifols had previously disclosed that it had a 30-year supply agreement with Scranton, it hadn't revealed any information on how prices were set. The deal was signed in 2018 and stipulated that Grifols would buy all the plasma from two companies owned by Scranton, Haema and BPC. Scranton, which is owned by members of the Grifols family and acquaintances, had acquired Haema and BPC from Grifols the same year. In a statement in response to Bloomberg questions, Grifols denied any illicit enrichment and said that all explanations related to the transactions have already been given to the securities regulator CNMV. The disclosures are emerging in documents in a court fight between Grifols and short seller Gotham City Research, and once again raise questions about the company's governance. In a January 2024 short-selling report, New York-based Gotham had accused Grifols of misleading investors and misstating its accounting —- claims denied by the Barcelona-based company. Business dealings between Grifols and Scranton had been at the heart of Gotham's attack. Grifols and Scranton subsequently took Gotham to court in Spain while Grifols also filed a lawsuit against the short seller in New York. The regulator documents filed with the court also show that Grifols specifically asked the Spanish securities agency CNMV in 2019 not to publicly disclose the pricing deal. In a statement to Bloomberg, Grifols said it never made the request. 'These are matters that fall within the jurisdiction of the affected company, and it is the company that must decide whether to make them public,' the CNMV said in a response to questions regarding the disclosures. Gotham declined to comment. Scranton representatives didn't reply to several calls and emails seeking comment. According to the court documents, Grifols told the securities regulator that the sale of Haema and BPC was unanimously approved on Dec. 24, 2018, by members of its board who had no links to Scranton, but didn't address the regulator's questions about whether conflicted directors took part in the deliberations prior to the vote. Grifols also told the CNMV that the fairness opinion letter for Scranton's acquisition of Haema and BPC was produced by then Chief Financial Officer Alfredo Arroyo, who retired from the company last year. Arroyo declined to comment when contacted by Bloomberg. Fairness opinions are typically written by investment banks or independent valuation firms and help boards with their financial assessment. The Spanish court is assessing whether Gotham published potentially misleading or biased information about Grifols. The court's fact-finding process in the case includes various reports produced by the securities regulator CNMV — one focusing on whether Gotham's actions could amount to market manipulation and another examining alleged shortcomings in Grifols' financial disclosures. Following the Gotham report, Grifols removed family members from top management positions and also named outsiders as chief executive officer and CFO. More stories like this are available on
Bloomberg
23-06-2025
- Business
- Bloomberg
Grifols Case Shows It Paid Family-Linked Entity More for Plasma
Spanish drugmaker Grifols SA paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator's findings submitted in a court case. Grifols paid Scranton Enterprises BV — one of its main shareholders — between 2% and 39% more annually for plasma than it paid other suppliers over five years, according to a document from the securities regulator filed with a Spanish court. Grifols also agreed to pay a fixed 16.5% mark up on costs to Scranton, according to the documents, which were seen by Bloomberg.
